tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Quest Diagnostics (DGX) and NeoGenomics (NEO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on IQVIA Holdings (IQVResearch Report), Quest Diagnostics (DGXResearch Report) and NeoGenomics (NEOResearch Report).

IQVIA Holdings (IQV)

In a report issued on July 21, Justin Bowers from Deutsche Bank maintained a Buy rating on IQVIA Holdings, with a price target of $290.00. The company’s shares closed last Friday at $221.74.

According to TipRanks.com, Bowers is a 4-star analyst with an average return of 8.2% and a 51.2% success rate. Bowers covers the Healthcare sector, focusing on stocks such as Select Medical, Amedisys, and Icon.

Currently, the analyst consensus on IQVIA Holdings is a Strong Buy with an average price target of $262.13, representing a 15.4% upside. In a report issued on July 15, SVB Securities also initiated coverage with a Buy rating on the stock with a $256.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Quest Diagnostics (DGX)

In a report issued on July 22, Pito Chickering from Deutsche Bank maintained a Hold rating on Quest Diagnostics, with a price target of $129.00. The company’s shares closed last Friday at $131.03, close to its 52-week low of $125.33.

According to TipRanks.com, Chickering is a 2-star analyst with an average return of 0.4% and a 39.6% success rate. Chickering covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Bausch + Lomb Corporation, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Quest Diagnostics is a Hold with an average price target of $146.11, a 7.6% upside from current levels. In a report issued on July 8, Robert W. Baird also maintained a Hold rating on the stock with a $148.00 price target.

NeoGenomics (NEO)

In a report issued on July 22, Mark Massaro from BTIG reiterated a Buy rating on NeoGenomics, with a price target of $23.00. The company’s shares closed last Friday at $9.48, close to its 52-week low of $6.85.

According to TipRanks.com, Massaro is a 3-star analyst with an average return of 1.1% and a 44.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Adaptive Biotechnologies, and Ginkgo Bioworks Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for NeoGenomics with a $16.50 average price target, implying a 73.9% upside from current levels. In a report issued on July 21, SVB Securities also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IQV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More